Yacktman Asset Management LP Acquires 232,631 Shares of Kenvue Inc. (NYSE:KVUE)

Yacktman Asset Management LP grew its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 2.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,381,404 shares of the company’s stock after purchasing an additional 232,631 shares during the period. Kenvue comprises 2.0% of Yacktman Asset Management LP’s holdings, making the stock its 20th largest holding. Yacktman Asset Management LP owned 0.44% of Kenvue worth $193,862,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in KVUE. Leo Wealth LLC lifted its holdings in shares of Kenvue by 0.3% during the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock worth $3,507,000 after acquiring an additional 481 shares during the period. Massmutual Trust Co. FSB ADV raised its stake in Kenvue by 6.2% during the third quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock worth $194,000 after acquiring an additional 492 shares in the last quarter. Wolff Wiese Magana LLC lifted its holdings in shares of Kenvue by 0.7% in the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after acquiring an additional 501 shares during the last quarter. Marathon Capital Management boosted its stake in shares of Kenvue by 0.3% in the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock valued at $2,722,000 after purchasing an additional 514 shares in the last quarter. Finally, Manchester Capital Management LLC grew its holdings in shares of Kenvue by 80.8% during the 1st quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after purchasing an additional 530 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Trading Up 1.4 %

NYSE KVUE opened at $23.04 on Tuesday. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $23.55. The business has a 50 day moving average price of $22.55 and a 200-day moving average price of $20.45. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. The company has a market cap of $44.13 billion, a price-to-earnings ratio of 39.72, a P/E/G ratio of 2.97 and a beta of 1.36.

Kenvue (NYSE:KVUE) last posted its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. The company had revenue of $4 billion for the quarter, compared to analyst estimates of $3.93 billion. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The firm’s revenue was down .3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.32 EPS. As a group, equities analysts expect that Kenvue Inc. will post 1.08 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be given a dividend of $0.205 per share. The ex-dividend date is Wednesday, November 13th. This represents a $0.82 annualized dividend and a dividend yield of 3.56%. Kenvue’s payout ratio is 141.38%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of a number of research reports. UBS Group boosted their target price on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft boosted their price objective on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. increased their target price on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Royal Bank of Canada cut Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target on the stock. in a report on Tuesday, September 24th. Finally, Bank of America raised their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Kenvue has a consensus rating of “Hold” and an average price target of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.